Market by Type (Expanded Polytetrafluoroethylene (ePTFE), Polyurethane, Polyethylene Terephthalate (PET), Other Types) Blood Vessel Diameter (Large , Medium, Small) Patient Demographic (Adult, Pediatric) Application (Aortic Disease, Peripheral Artery, Hemodialysis) End-User (Hospital, Specialty Clinics, Ambulatory Surgical Center, Other End-User) and Country Outlook | Forecast 2024-2032
As per Triton’s report, the Asia-Pacific artificial blood vessels market is estimated to progress in revenue at a CAGR of 6.53% during the forecast period 2024-2032.
Report scope can be customized per your requirements - Request Free Sample Report
The artificial blood vessels market in the Asia-Pacific region is growing rapidly, supported by significant advances in healthcare technologies and government-backed medical innovations. Countries like China and South Korea have been at the forefront, with China marking a notable achievement through the approval of the first domestically manufactured artificial blood vessel by Jiangsu Bioda Life Science Co, supported by the National Medical Products Administration (NMPA). This approval highlights China’s growing capabilities in med-tech innovation and regulatory support for advanced medical devices.
In South Korea, research institutions like the Korea Institute of Science and Technology (KIST) are developing artificial blood vessels using tissue engineering. This research is pivotal for improving organ transplant outcomes by simulating blood flow and pressure to reduce risks like clot formation. These developments are part of broader government healthcare initiatives across the region aimed at addressing the rise in cardiovascular diseases, promoting biotechnology research, and fostering innovation within the med-tech sector.
The countries reviewed in this region include:
China leads with a major share, accounting for $226.14 million in 2023
Government healthcare initiatives and technological advancements drive the Chinese artificial blood vessels market. China’s ‘Healthy China 2030’ strategy provides a strong foundation for the development of advanced medical devices, including artificial blood vessels. This initiative focuses on addressing non-communicable diseases like cardiovascular conditions, which are major drivers for the adoption of artificial blood vessels.
The government has been actively promoting local production. For example, Jiangsu Bioda Life Science Co, based in Chongchuan district, commenced the mass production of the first domestic artificial blood vessels in 2023, marking a significant milestone for the industry.
These efforts are further supported by policies under the 14th Five-Year Plan (2021–2025), which focuses on healthcare innovation and improving health infrastructure, creating opportunities for the adoption of innovative treatments such as artificial blood vessels.
Market Forecast for South Korea
The South Korean government has prioritized innovation in healthcare, particularly in the development of high-tech medical devices. The Ministry of Health and Welfare (MOHW) and the Ministry of Food and Drug Safety (MFDS) are actively streamlining regulations to facilitate the development and approval of innovative medical technologies. This includes creating guidelines that promote AI and digital healthcare enhancing the environment for medical device companies to bring advanced products to market faster. Hence, these factors create novel opportunities for growth in the artificial blood vessels market.
The market is segmented based on type, blood vessel diameter, patient demographic, application, and end-user. Based on blood vessel diameter, it is sectioned into large, medium, and small.
Large artificial blood vessel grafts typically have a diameter ranging from 6 mm to 30 mm or larger, designed to replace or bypass major blood vessels like the aorta, iliac arteries, or femoral arteries. These grafts are engineered to withstand the high pressures and flow rates associated with the cardiovascular system’s major blood vessels. Large artificial blood vessel grafts are commonly used in procedures such as aortic aneurysm repair, where a section of the aorta, the body’s main artery, is replaced with a synthetic graft. The selection of the appropriate graft material and design for large blood vessel applications depends on various factors, including the specific location and diameter of the vessel being replaced, the anticipated blood flow rates and pressures, and the patient’s characteristics.
Contender Analysis in the Artificial Blood Vessels Market:
Jiangsu Bioda Life Science Co Ltd specializes in developing, producing, and distributing in vitro diagnostic products and equipment. Its range includes diagnostic reagents, instruments, and accessories, serving clinical laboratories and healthcare institutions. The company operates manufacturing facilities and has established sales channels, supplying its products both within China and internationally. Based in Jiangsu, China, it is active in both domestic and global markets.
The company’s product line includes the tubular woven membrane constructed from polyester with thicknesses ranging from 40μm to 70μm. It is customizable in size, accommodating varied applications.
Other notable companies in the market include Medtronic Plc, WL Gore and Associates Inc, Roumai Medical, and Lemaitre Vascular Inc.
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the artificial blood vessels market revenue growth in the Asia-Pacific and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the APAC artificial blood vessels market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– SUMMARY
2. INDUSTRY OUTLOOK
2.1. PORTER’S FIVE FORCES ANALYSIS
2.1.1. THREAT OF NEW ENTRANTS
2.1.2. THREAT OF SUBSTITUTES
2.1.3. BARGAINING POWER OF BUYERS
2.1.4. BARGAINING POWER OF SUPPLIERS
2.1.5. THREAT OF COMPETITIVE RIVALRY
2.2. MARKET MATURITY ANALYSIS
2.3. SUPPLY CHAIN ANALYSIS
2.3.1. RAW MATERIALS
2.3.2. MANUFACTURERS
2.3.3. DISTRIBUTORS
2.3.4. END-USER
2.4. REGULATORY FRAMEWORK
2.5. KEY BUYING IMPACT ANALYSIS
2.5.1. BIOCOMPATIBILITY
2.5.2. DURABILITY AND LONGEVITY
2.5.3. CUSTOMIZATION AND VERSATILITY
2.5.4. REGULATORY COMPLIANCE AND QUALITY ASSURANCE
2.6. KEY MARKET STRATEGIES
2.6.1. COLLABORATIONS
2.6.2. PRODUCT LAUNCHES
2.6.3. ACQUISITIONS
2.6.4. BUSINESS DIVESTITURES & EXPANSIONS
2.7. MARKET DRIVERS
2.7.1. RISING RATES OF CARDIOVASCULAR DISEASES AND
VASCULAR DISORDERS
2.7.2. DEVELOPMENTS IN TISSUE ENGINEERING AND
REGENERATIVE MEDICINE
2.7.3. AGING POPULATION AND SHIFTING LIFESTYLES
2.8. MARKET CHALLENGES
2.8.1. EXPENSES IN THE DEVELOPMENT AND
COMMERCIALIZATION OF ARTIFICIAL BLOOD VESSELS
2.8.2. STRICT REGULATORY APPROVALS AND CLINICAL
TRIAL REQUIREMENTS
2.8.3. CHALLENGES RELATED TO BIOCOMPATIBILITY AND
LONG-TERM DURABILITY
2.9. MARKET OPPORTUNITIES
2.9.1. ADVANCEMENTS IN 3D BIOPRINTING FOR TAILORED
VASCULAR GRAFTS
2.9.2. USE OF NANOTECHNOLOGY AND BIOMIMETIC
MATERIALS TO ENHANCE FUNCTIONALITY
2.10. ANALYST PERSPECTIVE
3. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– BY TYPE
3.1. EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE)
3.2. POLYETHYLENE TEREPHTHALATE (PET)
3.3. POLYURETHANE
3.4. OTHER TYPES
4. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– BY BLOOD VESSEL DIAMETER
4.1. LARGE
4.2. MEDIUM
4.3. SMALL
5. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– BY PATIENT DEMOGRAPHIC
5.1. PEDIATRIC
5.2. ADULT
6. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– BY APPLICATION
6.1. PERIPHERAL ARTERY
6.2. HEMODIALYSIS
6.3. AORTIC DISEASE
7. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– BY END-USER
7.1. HOSPITAL
7.2. SPECIALTY CLINIC
7.3. AMBULATORY SURGICAL CENTER
7.4. OTHER END-USERS
8. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
– BY COUNTRY OUTLOOK
8.1. ASIA-PACIFIC
8.1.1. CHINA
8.1.1.1. CHINA ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.2. JAPAN
8.1.2.1. JAPAN ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.3. INDIA
8.1.3.1. INDIA ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.4. SOUTH KOREA
8.1.4.1. SOUTH KOREA ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.1.5. ASEAN COUNTRIES
8.1.5.1. ASEAN COUNTRIES ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.1.6. AUSTRALIA & NEW ZEALAND
8.1.6.1. AUSTRALIA & NEW
ZEALAND ARTIFICIAL BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.1.7. REST OF ASIA-PACIFIC
8.1.7.1. REST OF ASIA-PACIFIC ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
9. COMPETITIVE LANDSCAPE
9.1. BECTON, DICKINSON AND COMPANY
9.1.1. OVERVIEW
9.1.2. PORTFOLIO
9.1.3. KEY STRENGTHS
9.1.4. KEY CHALLENGE
9.2. LEMAITRE VASCULAR INC
9.2.1. OVERVIEW
9.2.2. PORTFOLIO
9.2.3. KEY STRENGTHS
9.2.4. KEY CHALLENGE
9.3. MEDTRONIC PLC
9.3.1. OVERVIEW
9.3.2. PORTFOLIO
9.3.3. KEY STRENGTH
9.3.4. KEY CHALLENGE
9.4. TERUMO MEDICAL CORPORATION
9.4.1. OVERVIEW
9.4.2. PORTFOLIO
9.4.3. KEY STRENGTHS
9.4.4. KEY CHALLENGE
9.5. W. L. GORE AND ASSOCIATES INC
9.5.1. OVERVIEW
9.5.2. PORTFOLIO
9.5.3. KEY STRENGTHS
9.5.4. KEY CHALLENGES
9.6. GETINGE AB
9.6.1. OVERVIEW
9.6.2. PORTFOLIO
9.6.3. KEY STRENGTHS
9.6.4. KEY CHALLENGE
9.7. ROUMAI MEDICAL
9.7.1. OVERVIEW
9.7.2. PORTFOLIO
9.7.3. KEY STRENGTHS
9.7.4. KEY CHALLENGES
9.8. MEDICALEXPO
9.8.1. OVERVIEW
9.8.2. PORTFOLIO
9.8.3. KEY STRENGTHS
9.8.4. KEY CHALLENGES
9.9. VASCULAR GRAFT SOLUTIONS
9.9.1. OVERVIEW
9.9.2. PORTFOLIO
9.9.3. KEY STRENGTHS
9.9.4. KEY CHALLENGES
9.10. JIANGSU BIODA LIFE SCIENCE CO LTD
9.10.1. OVERVIEW
9.10.2. PORTFOLIO
9.10.3. KEY STRENGTHS
9.10.4. KEY CHALLENGE
10. RESEARCH METHODOLOGY & SCOPE
10.1. RESEARCH SCOPE & DELIVERABLES
10.2. SOURCES OF DATA
10.3. RESEARCH METHODOLOGY
TABLE 1: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY
OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE,
2024-2032 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2024-2032 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER,
2024-2032 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY
OUTLOOK, 2024-2032 (IN $ MILLION)
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: SUPPLY CHAIN ANALYSIS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE, 2023
& 2032 (IN %)
FIGURE 5: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY EXPANDED
POLYTETRAFLUOROETHYLENE (EPTFE), 2024-2032 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY POLYETHYLENE
TEREPHTHALATE (PET), 2024-2032 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY POLYURETHANE,
2024-2032 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY OTHER TYPES,
2024-2032 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2023 & 2032 (IN %)
FIGURE 10: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY LARGE,
2024-2032 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY MEDIUM,
2024-2032 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY SMALL,
2024-2032 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2023 & 2032 (IN %)
FIGURE 14: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY PEDIATRIC,
2024-2032 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY ADULT,
2024-2032 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2023 & 2032 (IN %)
FIGURE 17: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY PERIPHERAL
ARTERY, 2024-2032 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY HEMODIALYSIS,
2024-2032 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY AORTIC
DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER,
2023 & 2032 (IN %)
FIGURE 21: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY HOSPITAL,
2024-2032 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY SPECIALTY
CLINIC, 2024-2032 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY ONLINE
PHARMACY, 2024-2032 (IN $ MILLION)
FIGURE 24: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY OTHER
END-USERS, 2024-2032 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY
OUTLOOK, 2023 & 2032 (IN %)
FIGURE 26: CHINA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 27: JAPAN ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 28: INDIA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 29: SOUTH KOREA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 30: ASEAN COUNTRIES ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN
$ MILLION)
FIGURE 31: AUSTRALIA & NEW ZEALAND ARTIFICIAL BLOOD VESSELS MARKET 2024-2032
(IN $ MILLION)
FIGURE 32: REST OF ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET 2024-2032
(IN $ MILLION)